Effect of protein kinase Cβ inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study

DZI Cherney, A Konvalinka, B Zinman… - Diabetes …, 2009 - Am Diabetes Assoc
DZI Cherney, A Konvalinka, B Zinman, EP Diamandis, A Soosaipillai, H Reich, J Lorraine…
Diabetes care, 2009Am Diabetes Assoc
OBJECTIVE—The aim of this study was to examine the effect of protein kinase Cβ inhibition
with ruboxistaurin on renal hemodynamic function and urinary biomarkers (monocyte
chemoattractant protein-1 [MCP-1] and epidermal growth factor) in renin angiotensin system
blockade-treated type 1 diabetic subjects. RESEARCH DESIGN AND METHODS—
Albuminuric subjects were randomized (2: 1) to ruboxistaurin (32 mg daily; n= 13) or
placebo (n= 7) for 8 weeks. Renal hemodynamic function was measured during clamped …
OBJECTIVE—The aim of this study was to examine the effect of protein kinase Cβ inhibition with ruboxistaurin on renal hemodynamic function and urinary biomarkers (monocyte chemoattractant protein-1 [MCP-1] and epidermal growth factor) in renin angiotensin system blockade-treated type 1 diabetic subjects.
RESEARCH DESIGN AND METHODS—Albuminuric subjects were randomized (2:1) to ruboxistaurin (32 mg daily; n = 13) or placebo (n = 7) for 8 weeks. Renal hemodynamic function was measured during clamped euglycemia or hyperglycemia and before and after ruboxistaurin or placebo.
RESULTS—Ruboxistaurin was not associated with between-group differences during clamped euglycemia or hyperglycemia. In a post hoc analysis comparing hyperfilterers with normofilterers during euglycemia, glomerular filtration rate and MCP-1 decreased, whereas the epidermal growth factor–to–MCP-1 ratio increased in hyperfilterers versus normofilterers (all P < 0.05).
CONCLUSIONS—The effect of ruboxistaurin is modest and dependent, at least in part, on the level of ambient glycemia and baseline glomerular filtration rate.
Am Diabetes Assoc